Drug Trial Radar · NCT06931405
Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
110
Actual
Start
May 28, 2025
Primary completion
Oct 15, 2026
Study completion Oct 15, 2026
Sponsor
- Lead sponsor
- Blueprint Medicines CorporationIndustry
- Sponsor type
- Industry
- First posted
- Apr 17, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a 2-part, proof-of-concept study to be conducted globally, designed to evaluate the safety, tolerability, clinical activity, pharmacokinetics, and pharmacodynamics of BLU-808, a wild type KIT inhibitor, in participants with CIndU (Part A) or CSU (Part B).
Conditions
- Chronic Inducible Urticaria
- Chronic Spontaneous Urticaria
Interventions
BLU-808Drug
Oral administration
PlaceboDrug
Oral administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A and Part B: Number of Participants with Treatment-emergent Adverse Events (TEAEs)Time frame: Day 1 through Week 16
Locations
47 sites in 6 countries. Site status is shown where the registry gives one.
Allervie Clinical Research
Birmingham, Alabama
Acuro Research, Inc.
Little Rock, Arkansas
Modena Allergy & Asthma Clinical Research - La Jolla
La Jolla, California
Allergy & Asthma Associates of Southern California
Laguna Niguel, California
Allergy & Asthma Medical Group and Research Center
San Diego, California
Allergy Affiliates Inc.
Bradenton, Florida
University of South Florida
Tampa, Florida
Treasure Valley Medical Research
Boise, Idaho
Endeavor Health
Northbrook, Illinois
Dawes Fretzin Clinical Research Group, LLC
Indianapolis, Indiana
Southern Indiana Clinical Trials
New Albany, Indiana
The Indiana Clinical Trials Center
Plainfield, Indiana
Equity Medical - Bowling Green
Bowling Green, Kentucky
Johns Hopkins University
Baltimore, Maryland
Institute For Asthma & Allergy
Wheaton, Maryland
Chesapeake Clinical Research
White Marsh, Maryland
Henry Ford Health
Detroit, Michigan
Mayo Clinic
Rochester, Minnesota
The Clinical Research Center LLC.
St Louis, Missouri
Montana Medical Research, Inc.
Missoula, Montana
Equity Medical (at Cameron Dermatology) - New York
New York, New York
Bernstein Clinical Research Center
Cincinnati, Ohio
Allergy & Clinical Immunology Associates
Pittsburgh, Pennsylvania
National Allergy, Asthma & Urticaria Centers of Charleston
Charleston, South Carolina
Medical University of South Carolina (MUSC)
Charleston, South Carolina
Reveal Research Institute
Dallas, Texas
Austin Institute for Clinical Research
Pflugerville, Texas
Odense University Hospital - Odense
Odense, Denmark
Fraunhofer-Institut fuer Translationale Medizin und Pharmakologie ITMP - Standort Berlin
Berlin, Germany
Universitaetsklinikum Carl Gustav Carus Dresden
Dresden, Germany
Universitaetsklinikum Frankfurt - Klinikum der Johann Wolfgang Goethe Universitaet
Frankfurt am Main, Germany
Medizinische Hochschule Hannover (MHH)
Hanover, Germany
Universitaetsmedizin der Johannes Gutenberg - Universitaet Mainz
Mainz, Germany
Universitaetsklinikum Tuebingen
Tübingen, Germany
Azienda Ospedale - Università Padova
Padova, Italy
Azienda Ospedaliero Universitaria Policlinico Umberto
Rome, Italy
Centro Ricerche Cliniche di Verona s.r.l.
Verona, Italy
Hospital del Mar
Barcelona, Spain
Hospital Universitario Vall d'Hebron
Barcelona, Spain
Hospital Universitari de Bellvitge
Barcelona, Spain
Showing 40 of 47 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.